Emerging evidence has revealed that in addition to EGFR TKI therapy failure, AST has also been observed in other molecular targeted therapy resistance of lung cancer, e.g. in lung cancer patients who have relapsed from ALK inhibitor treatment [61] or KrasG12C inhibitor adagrasib treatment [62]. This evidence concerns the gene ALK and lung carcinoma.